Oxford Biomedica plc has signed new Licence and Supply Agreement ("LSA") with Arcellx Inc. ("Arcellx"), a Gaithersburg MD.-based biotechnology company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. The LSA grants Arcellx a non-exclusive licence to Oxford Biomedica's LentiVector® platform for its application in select Arcellx CAR-T programmes and puts in place a three-year Clinical Supply Agreement. Under the terms of the LSA, Oxford Biomedica will receive payments related to the development and manufacturing of lentiviral vectors for use in clinical trials. Additionally, the agreement allows for payments to the Group for the manufacture and supply of lentiviral vectors for commercial use. This partnership with a leader in the CAR-T field builds on the longstanding partnerships with Novartis and Bristol Myers Squibb, as well as the more recently announced partnership with Beam Therapeutics.